Biocon Expands Global Footprint with Landmark Diabetes Drug Launch and Strong FY25 Growth

From GLP-1 breakthrough to insulin leadership, Biocon eyes high-growth markets with robust pipeline and capacity expansion

Biocon Limited reported steady growth in FY25, advancing its mission to expand access to essential medicines globally. Consolidated revenue rose 5% to ₹1,64,699 million, with EBITDA up 5% at ₹43,745 million and net profit at ₹10,133 million. The biosimilars segment led the performance with 15% growth, followed by 8% growth in generics and 4% in research services.

A key milestone was the UK launch of generic Liraglutide—Biocon’s first GLP-1 therapy—marking its entry into the high-growth ‘diabesity’ market. With this, Biocon became the only company worldwide to offer a generic GLP-1 product alongside two interchangeable biosimilar insulins. EU approvals and U.S. filings are in place for Semaglutide and Tirzepatide, targeting a projected USD 144 billion GLP-1 market by 2029.

The biosimilars business also achieved a landmark with U.S. FDA approval for interchangeable Biosimilar Insulin Aspart (Kirsty), making Biocon the only player with two interchangeable biosimilar insulins in the U.S. Expansion of its Malaysia facility will double insulin production capacity, and a partnership with U.S.-based Civica will further strengthen supply capabilities.

In generics, the launch of Yesintek, a biosimilar for inflammatory diseases, saw strong U.S. adoption, while oncology market share doubled. Research arm Syngene expanded biologics capabilities through a U.S. facility acquisition and a next-gen protein production platform.

Biocon also strengthened its balance sheet, raising USD 800 million via Biocon Biologics bonds and ₹45 billion through a QIP. With innovation, capacity expansion, and strong financials, Biocon is positioned for sustained global growth.

Biocon Limited is a leading biotechnology company engaged in manufacturing biologics, biosimilars, and specialty generics, along with providing integrated research services to global clients.

This article is intended for informational purposes only and should not be considered as investment advice.